– USA, NC – Polarean Imaging plc (LON: POLX), the medical‑imaging technology company, today announced the appointment of Dr. Marcella Ruddy (MD) to its Board as a Non-Executive Director with immediate effect.
“Marcie is a recognised leader in clinical development with experience across a broad range of indications, including respiratory therapeutics. Her broad expertise in all stages of drug development as well as her demonstrated capability in building and leading clinical development teams will be invaluable to us and we look forward to her guidance and specific insights into the industry. She has a wealth of experience and knowledge and I believe Polarean will greatly benefit from having her on the Board.” said CEO, Richard Hullihen.
About Dr. Marcella Ruddy
Dr. Ruddy has over 15 years of experience developing respiratory and other therapeutic compounds across all stages of clinical development from translational through post-approval. She has held multiple senior management positions over her c date, including Merck & Co., Inc., Alnylam Pharmaceuticals, Inc, Regeneron Pharmaceuticals, Inc,d at Tectonic Therapeutic where she has been employed as CMO since July 2021.
Dr. Ruddy is a board-certified pulmonologist who before entry into drug development, held a staff position in the Pulmonary Unit at Massachusetts General Hospital/Harvard Medical School where she founded and directed the Adult Cystic Fibrosis Programme. Earlier in her career, she completed her Internal Medicine Residency and Pulmonary Critical Care Fellowship training at Harvard Medical School and associated medical centers.
Dr. Ruddy holds an AB (Bachelor of Arts) from Princeton University and an MD (Doctor of Medicine) from Washington University, St Louis.
About Polarean
The Company and its wholly owned subsidiary, Polarean, Inc. are revenue-generating, investigational drug-device combination companies operating in the high-resolution medical imaging research space.
The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specializes in the use of hyperpolarised Xenon gas (129Xe) as an imaging agent to visualize ventilation. 129Xe gas is currently being studied for visualization of gas exchange regionally in the smallest airways of the lungs, across the alveolar tissue membrane, and into the pulmonary bloodstream.
In October 2020, the Group submitted a New Drug Application to the FDA for hyperpolarised 129Xe to evaluate the pulmonary function and visualize the lung using MRI. The Group received a complete response letter on 5 October 2021. On 30 March 2022, the Company filed the resubmission of its NDA with the US FDA and has received a PDUFA date of Sept 30, 2022.
The Group operates in an area of significant unmet medical need and the Group’s technology provides a novel investigational diagnostic approach, offering a non-invasive and radiation-free functional imaging platform.
For more information: https://polarean.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
